Analyst Price Target is $10.50
▲ +430.30% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cybin in the last 3 months. The average price target is $10.50, with a high forecast of $15.00 and a low forecast of $8.00. The average price target represents a 430.30% upside from the last price of $1.98.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Cybin.
Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.